Dated disclosed rounds · latest 2024-01-02
Later stage / growth
Apollo Therapeutics
Pharma/academia JV biopharmaceutical drug discovery
VerifiedSeries C (second close)Cambridge
- Companies House
- 13393274
- GLEIF LEI
- Not matched
- Latest evidence
- 2024-01-02
- Evidence snapshot
- 2026-08-25
Exact award notices · latest No exact award match
2026-08-01
Jun 2026
Signals organise dated evidence; they do not score growth, revenue, creditworthiness or investment performance.
Evidence timeline
6 dated observations
Funding, procurement, registry and identifier records are placed on one chronology. Each row says whether it is a source fact, a record observation or reference metadata; no inferred event is inserted.
RegistryRecord observation Status observed: Active
Snapshot evidence only; this row does not claim the status changed on this date.
FundingSource fact Series C (second close)
$33.5M · 3 named investors
FundingSource fact Series C
$226.5M · 2 named investors
FundingSource fact Series B
$145M · 4 named investors
RegistryRegistry fact Company incorporated
APOLLO THERAPEUTICS GROUP LIMITED · company 13393274
FundingSource fact Formation (JV)
£40M · 6 named investors
Latest disclosed round
Series C (second close)
- Date
- 2024-01-02
- Amount
- USD 33.5m
- Sector
- Biotech & techbio
- Companies House
- 13393274
- ONS region
- East
Evidence status
Directory ready
- Identity
- Verified
- Match
- High — exact company number and aligned registered name
- Operating status
- active
- Data origins
- Core directory, Live Chris T D1
Capital network
12 linked investors
Lead, participant, lender and other retained roles remain distinct where the source supports them. Every relationship below names its source layer, observation date, match method and publication state.
AstraZenecaleadGSKleadJohnson & Johnson InnovationleadPatient Square CapitalleadCambridge EnterpriseparticipantImperial InnovationsparticipantM&G plcparticipantReimagined VenturesparticipantRock Springs Capitalparticipanttwo large US public pension plansparticipantUCL BusinessparticipantUCL Technology Fundparticipant
| Investor | Role | Date | Source | Match / state |
|---|---|---|---|---|
| AstraZeneca | lead | 2016-01-25 | Uclb ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| GSK | lead | 2016-01-25 | Uclb ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Johnson & Johnson Innovation | lead | 2016-01-25 | Uclb ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Patient Square Capital | lead | 2023-09-06 | Business Wire ↗ · Business Wire ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Cambridge Enterprise | participant | 2016-01-25 | Uclb ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Imperial Innovations | participant | 2016-01-25 | Uclb ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| M&G plc | participant | 2024-01-02 | Business Wire ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Reimagined Ventures | participant | 2021-06-16 | Business Wire ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Rock Springs Capital | participant | 2024-01-02 | Business Wire ↗ · Business Wire ↗ · Business Wire ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| two large US public pension plans | participant | 2024-01-02 | Business Wire ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| UCL Business | participant | 2016-01-25 | Uclb ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| UCL Technology Fund | participant | 2021-06-16 | Business Wire ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
Funding record
4 disclosed rounds
Open a dated round to move directly between the company, named investors and source publication.
| Date | Stage | Amount | Investors | Named sources |
|---|---|---|---|---|
| 2024-01-02 | Series C (second close) | $33.5M | M&G plc · Rock Springs Capital · two large US public pension plans | Business Wire ↗ |
| 2023-09-06 | Series C | $226.5M | Patient Square Capital · Rock Springs Capital | Business Wire ↗ |
| 2021-06-16 | Series B | $145M | Patient Square Capital · Rock Springs Capital · Reimagined Ventures · UCL Technology Fund | Business Wire ↗ |
| 2016-01-25 | Formation (JV) | £40M | AstraZeneca · GSK · Johnson & Johnson Innovation · Cambridge Enterprise · Imperial Innovations · UCL Business | Uclb ↗ |
Companies House status and filing snapshot
APOLLO THERAPEUTICS GROUP LIMITED
Exact company-number match from the public register. The retained status is active. Filing dates and SIC codes are registry context, not a credit or investment-quality assessment.
Registered record
- Status
- Active
- Company type
- Private Limited Company
- Country of origin
- United Kingdom
- Incorporated
- 2021-05-13
- Dissolved
- Not applicable
- Company number
- 13393274
Filing context
- Accounts category
- GROUP
- Accounts made up to
- 2025-12-31
- Next accounts due
- 2027-09-30
- Confirmation made up to
- 2026-05-12
- Registry snapshot
- 2026-08-01
- Live check
- Bulk snapshot only
Former registered names: AT TOPCO LIMITED
64209Activities of other holding companies n.e.c.
Traceability
Source trail
Funding and investor claims retain named public-source links. This is a dated research snapshot, not a live cap table.